Manage prostate enlargement with personalised, ongoing care.

Watchful waiting is active monitoring - not "doing nothing." It's the appropriate approach for men with mild symptoms (typically IPSS score below 8), no significant complications, and no significant impact on quality of life.

What's involved: annual IPSS assessment to track symptom progression, annual PSA and digital rectal exam, lifestyle modifications, and education on when to seek earlier review.

Lifestyle modifications with evidence: fluid timing (reduce evening fluid intake to minimise nocturia, maintain normal hydration during the day); caffeine and alcohol reduction (both irritate the bladder and worsen urgency and frequency); bladder retraining (scheduled voiding with gradual interval extension); double voiding (waiting 30 seconds and attempting to void again); pelvic floor exercises; weight management (obesity worsens BPH symptoms - medical weight loss is recommended where BMI is over 27); constipation management.

When to escalate from watchful waiting: IPSS score rises above 8 consistently, quality of life is meaningfully affected, complications develop (retention, recurrent UTIs, bladder stones), or patient preference for more active treatment.

Alpha-blockers are the most commonly prescribed first-line medication for symptomatic BPH. They work by relaxing smooth muscle in the prostate and bladder neck, reducing the mechanical obstruction without changing prostate size.

Common medications: Tamsulosin - most prostate-selective, lowest blood pressure effect, standard first choice; Alfuzosin - similar profile to tamsulosin; Silodosin - most prostate-selective, highest rate of retrograde ejaculation; Doxazosin and terazosin - older alpha-blockers, also lower blood pressure.

How they work: relax prostatic and bladder-neck smooth muscle, reducing urinary obstruction. Onset of symptom improvement within 1-2 weeks.

Effectiveness: studies show alpha-blockers improve IPSS by approximately 30-40% in most patients, with sustained effect over years (see source 2 below).

Eligibility: suitable for most patients with moderate symptoms. Caution in patients with orthostatic hypotension, recent cataract surgery (intraoperative floppy iris syndrome), or significant cardiovascular disease.

Side effects: dizziness (particularly when starting - first dose at bedtime), nasal congestion, retrograde ejaculation (semen flows into bladder during climax - common with silodosin and tamsulosin). Generally well-tolerated long-term.

5-alpha reductase inhibitors (5ARIs) work by reducing the conversion of testosterone to dihydrotestosterone (DHT) - the hormone that drives prostate growth. Over 6 months, this gradually shrinks the prostate by approximately 20-30%, reducing both symptoms and the risk of complications.

Common medications: Finasteride - blocks one type of 5-alpha reductase enzyme, daily oral; Dutasteride - blocks both types of the enzyme, more complete suppression, daily oral.

How they work: reduce DHT levels by 70-90%, leading to gradual prostate shrinkage and reduced symptoms. Effect builds over 3-6 months.

Effectiveness: studies show 5ARIs reduce the long-term risk of urinary retention by approximately 50% and the need for prostate surgery by 50% in men with larger prostates (see source 3 below). They also reduce PSA by approximately 50% - important to remember during prostate cancer screening.

Eligibility: best for men with larger prostates (>30g), men wanting long-term disease modification, or men who want to delay or avoid procedural treatment. Less effective for smaller prostates.

Side effects: reduced libido (3-5%), erectile difficulty (3-5%), reduced semen volume, occasionally breast tenderness. Most effects resolve when stopping. Persistent post-finasteride syndrome is reported but rare.

Important note on PSA: 5ARIs roughly halve PSA values. Any PSA result during 5ARI treatment must be doubled to compare against normal ranges.

Combination with alpha-blockers: for larger prostates with significant symptoms, combination therapy (alpha-blocker + 5ARI) is more effective than either alone - providing fast symptomatic relief (alpha-blocker) and long-term disease modification (5ARI).

Where medication is insufficient or complications develop, several procedural options exist. Hisential's role is to identify when procedural treatment is appropriate and coordinate referral to an MMC-registered urologist who specialises in these procedures.

Minimally invasive options: UroLift (Prostatic Urethral Lift) - small implants pull prostatic tissue away from the urethra, day procedure under local anaesthesia, preserves sexual function, suitable for smaller-to-moderate prostates; Rezum (water vapor therapy) - steam delivered into prostate tissue to gradually shrink it over weeks, day procedure, preserves sexual function; Prostatic artery embolisation (PAE) - interventional radiology procedure that reduces prostate blood supply, done under local anaesthesia.

Established surgical options: TURP (Transurethral Resection of the Prostate) - the gold standard for over 50 years, tissue removed transurethrally under spinal or general anaesthesia, excellent long-term outcomes but more invasive; Laser prostatectomy (HoLEP, GreenLight) - laser-based tissue removal, reduced bleeding compared to TURP, excellent outcomes; Simple prostatectomy - open or robotic surgery for very large prostates (>80g), reserved for selected cases.

When procedural treatment is considered: severe symptoms not adequately controlled by medication; complications (urinary retention, recurrent UTIs, bladder stones, kidney impairment); patient preference for one-time intervention over ongoing medication; larger prostates where medication alone has limited benefit.

Hisential's coordination: where procedural treatment is appropriate, your personal health concierge coordinates referral, manages pre-procedure assessments, and ensures continuity of care during and after treatment.